Cargando…

Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment

BACKGROUND: Combined therapy of transcatheter arterial chemoembolization (TACE) with sorafenib is used for a large number of patients with intermediate-stage or advanced-stage hepatocellular carcinoma (HCC), but its implementation is limited by the evaluation of pre-treatment liver function reserve....

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Keshu, Yuan, Jia, Tang, Bei, Zhang, Feng, Lu, Shenxin, Chen, Rongxin, Zhang, Lan, Ren, Zhenggang, Yin, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940911/
https://www.ncbi.nlm.nih.gov/pubmed/33708864
http://dx.doi.org/10.21037/atm-20-3118
_version_ 1783662044648570880
author Hu, Keshu
Yuan, Jia
Tang, Bei
Zhang, Feng
Lu, Shenxin
Chen, Rongxin
Zhang, Lan
Ren, Zhenggang
Yin, Xin
author_facet Hu, Keshu
Yuan, Jia
Tang, Bei
Zhang, Feng
Lu, Shenxin
Chen, Rongxin
Zhang, Lan
Ren, Zhenggang
Yin, Xin
author_sort Hu, Keshu
collection PubMed
description BACKGROUND: Combined therapy of transcatheter arterial chemoembolization (TACE) with sorafenib is used for a large number of patients with intermediate-stage or advanced-stage hepatocellular carcinoma (HCC), but its implementation is limited by the evaluation of pre-treatment liver function reserve. This study aimed to validate the performance of the albumin-bilirubin index (ALBI) and platelet-albumin-bilirubin index (PALBI) in predicting survival benefits in patients with HCC and Child-Pugh grade A receiving TACE combined with sorafenib treatment. METHODS: From 2004 to 2018, 418 patients with intermediate/advanced-stage HCC and Child-Pugh grade A receiving TACE combined with sorafenib treatment were retrospectively enrolled. The predictive performance of ALBI and PALBI was explored by survival analysis and receiver operating characteristic curve (ROC) analysis. RESULTS: The median overall survival (mOS) was 24 and 12 months in patients with ALBI grade 1 and grade 2, respectively. The mOS of patients with PALBI grade 1, grade 2, and grade 3 was 23, 16, and 7 months, respectively. The multivariate analysis showed that ALBI grade 2 [hazard ratio (HR) =1.39, 95% confidence interval (CI): 1.11–1.74] and PALBI grade 3 (HR =3.72, 95% CI: 2.26–6.06) were associated with unfavorable prognosis. The ROC analysis revealed that ALBI and PALBI scores had better prediction performance compared with the Child-Pugh score. Subgroup analysis confirmed that by using ALBI or PALBI, patients could be stratified into subgroups with different liver function reserves and distinctive prognosis, regardless of Barcelona Clinic Liver Cancer (BCLC) stage, combination modality, or α-fetoprotein (AFP) levels. CONCLUSIONS: Both ALBI and PALBI could predict prognosis in patients with HCC and Child-Pugh grade A receiving TACE and sorafenib. Patients with ALBI or PALBI grade 1 harbored a more favorable survival outcome compared with those with ALBI or PALBI grade 2–3, and hence should be recommended as the best candidates for TACE combined with sorafenib treatment.
format Online
Article
Text
id pubmed-7940911
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-79409112021-03-10 Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment Hu, Keshu Yuan, Jia Tang, Bei Zhang, Feng Lu, Shenxin Chen, Rongxin Zhang, Lan Ren, Zhenggang Yin, Xin Ann Transl Med Original Article BACKGROUND: Combined therapy of transcatheter arterial chemoembolization (TACE) with sorafenib is used for a large number of patients with intermediate-stage or advanced-stage hepatocellular carcinoma (HCC), but its implementation is limited by the evaluation of pre-treatment liver function reserve. This study aimed to validate the performance of the albumin-bilirubin index (ALBI) and platelet-albumin-bilirubin index (PALBI) in predicting survival benefits in patients with HCC and Child-Pugh grade A receiving TACE combined with sorafenib treatment. METHODS: From 2004 to 2018, 418 patients with intermediate/advanced-stage HCC and Child-Pugh grade A receiving TACE combined with sorafenib treatment were retrospectively enrolled. The predictive performance of ALBI and PALBI was explored by survival analysis and receiver operating characteristic curve (ROC) analysis. RESULTS: The median overall survival (mOS) was 24 and 12 months in patients with ALBI grade 1 and grade 2, respectively. The mOS of patients with PALBI grade 1, grade 2, and grade 3 was 23, 16, and 7 months, respectively. The multivariate analysis showed that ALBI grade 2 [hazard ratio (HR) =1.39, 95% confidence interval (CI): 1.11–1.74] and PALBI grade 3 (HR =3.72, 95% CI: 2.26–6.06) were associated with unfavorable prognosis. The ROC analysis revealed that ALBI and PALBI scores had better prediction performance compared with the Child-Pugh score. Subgroup analysis confirmed that by using ALBI or PALBI, patients could be stratified into subgroups with different liver function reserves and distinctive prognosis, regardless of Barcelona Clinic Liver Cancer (BCLC) stage, combination modality, or α-fetoprotein (AFP) levels. CONCLUSIONS: Both ALBI and PALBI could predict prognosis in patients with HCC and Child-Pugh grade A receiving TACE and sorafenib. Patients with ALBI or PALBI grade 1 harbored a more favorable survival outcome compared with those with ALBI or PALBI grade 2–3, and hence should be recommended as the best candidates for TACE combined with sorafenib treatment. AME Publishing Company 2021-02 /pmc/articles/PMC7940911/ /pubmed/33708864 http://dx.doi.org/10.21037/atm-20-3118 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Hu, Keshu
Yuan, Jia
Tang, Bei
Zhang, Feng
Lu, Shenxin
Chen, Rongxin
Zhang, Lan
Ren, Zhenggang
Yin, Xin
Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment
title Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment
title_full Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment
title_fullStr Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment
title_full_unstemmed Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment
title_short Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment
title_sort albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and child-pugh grade a undergoing transcatheter arterial chemoembolization with sorafenib treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940911/
https://www.ncbi.nlm.nih.gov/pubmed/33708864
http://dx.doi.org/10.21037/atm-20-3118
work_keys_str_mv AT hukeshu albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT yuanjia albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT tangbei albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT zhangfeng albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT lushenxin albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT chenrongxin albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT zhanglan albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT renzhenggang albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment
AT yinxin albuminbilirubinindexandplateletalbuminbilirubinindexcontributetoidentifyingsurvivalbenefitcandidatesinpatientswithhepatocellularcarcinomaandchildpughgradeaundergoingtranscatheterarterialchemoembolizationwithsorafenibtreatment